Related Experiment Video

Updated: Oct 17, 2025

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

3.0K

Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation

Omar Abdul-Jawad Altisent1, Rimantas Benetis2, Egle Rumbinaite3

  • 1Department of Cardiology, Germans Trias University Hospital, 08916 Badalona, Spain.

Journal of Clinical Medicine
|October 13, 2021
PubMed

Insights

Severe tricuspid regurgitation is difficult to treat. The bicaval valve implantation (CAVI) technique offers a promising alternative for many patients, though more research is needed.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Heart Valve Disease

Background:

  • Severe tricuspid regurgitation presents significant treatment challenges with high morbidity and mortality.
  • Current medical management is limited, and surgical interventions remain controversial.
  • Emerging percutaneous therapies show promise but lack robust randomized trial data and have patient selection limitations.

Purpose of the Study:

  • To review the current evidence and uncertainties surrounding the bicaval valve implantation (CAVI) technique for severe tricuspid regurgitation.
  • To highlight CAVI as a potentially suitable alternative for a broad patient population.
  • To focus on novel CAVI-specific devices.

Main Methods:

  • Review of existing literature on severe tricuspid regurgitation treatments.
  • Analysis of early feasibility studies for percutaneous therapies.
  • Focus on the technical aspects and patient suitability for CAVI.
  • Examination of novel CAVI devices.

Main Results:

  • Severe tricuspid regurgitation management remains challenging.
  • Percutaneous therapies show early promise but require further validation.
  • CAVI's technical simplicity suggests broad applicability.
  • Novel CAVI devices are emerging.

Conclusions:

  • CAVI is a potentially valuable option for severe tricuspid regurgitation, especially for patients unsuitable for other therapies.
  • Further research, including randomized trials, is necessary to establish CAVI's efficacy and long-term outcomes.
  • Ongoing development of CAVI-specific devices may expand treatment possibilities.

Keywords:
Transcatheter Valves Therapiesbicaval valve implantationreviewtricuspid regurgitation

More Related Videos

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.3K
Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement09:57

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement

Published on: January 20, 2022

2.8K

Related Concept Videos

Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
52
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
45
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
71
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
122
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
80
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
70